identify the effect of HRF in the T1HG population who were managed with either primary BCG or upfront radical cystectomy (RC).
identify the effect of HRF in the T1HG population who were managed with either primary BCG or upfront radical cystectomy (RC).
METHODS: With IRB approval, a single center retrospective review was performed on all patients with BC at MDACC from 1995-2013. All patients included underwent a re-resection for T1HG disease and had presence of HRF as defined by: presence of hydronephrosis, thickening or induration felt at exam under anesthesia, presence of lymphovascular invasion, presence of prostatic ductal involvement or the presence of variant histology. Patients were considered to have had BCG therapy if they underwent 6 weeks of induction therapy and started a maintenance course. Primary outcome included overall survival (OS) and disease specific survival (DSS). Secondary outcomes include pathological outcome at RC.
RESULTS: 209 patients with T1HG bladder cancer and HRF were identified, 64 patients (31%) had primary BCG and 145 (70%) had upfront RC. For patients with primary BCG, 2 had died and did not receive RC, 12 had BCG response and 50 patients had BCG failure and had a delayed RC (DRC). Median OS for primary BCG patients was 130 months vs. 137 for URC (p¼0.0467 on KM). A total 195 patients underwent RC. Time from diagnosis of T1HG to RC was 1.4 months for upfront RC compared to 10.3 months for DRC (p<0.001). 22% (32/145) of URC patients, and 10% (5/50) of DRC patients extravesical disease (p¼0.09). There was no significant difference in OS between RC patients who had upfront RC vs. DRC (p¼0.2117) . 10 year DSS post RC was 74.5% for upfront RC vs. 78% for DRC (p¼0.122).
CONCLUSIONS: T1HG BC with HRF is amenable to either upfront RC or primary BCG. Primary BCG is associated with worse OS compared to upfront RC. However, this includes patients who did not make it to RC. Of patients treated with BCG, 78% received RC. There was no adverse effects on outcome at DRC. This study validates the use of upfront RC in T1HG with HRF. As well, it demonstrates that primary BCG is a reasonable option as long as diligent follow up is maintained and a low threshold to proceed with RC upon recurrence is followed. 
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INTRODUCTION AND OBJECTIVES:
The association between the purified protein derivative (PPD) skin test reaction before intravesical BCG therapy and clinical outcomes of patients with nonmuscle invasive bladder cancer (NMIBC) has not been adequately investigated.
METHODS: A total of 288 patients with NMIBC who underwent complete TURBT and adjuvant intravesical BCG therapy between 1987 and 2015 were included. In all patients, skin reactivity to a PPD of mycobacterium tuberculosis was tested before BCG therapy. The PPD skin test reaction was classified into 3 categories; negative, erythema or induration. Erythema reaction of 10 mm or less in diameter was considered to be negative. We evaluated the association between the PPD skin test reaction and tumor recurrence as well as the occurrence of major side effects due to BCG.
RESULTS: The PPD skin test results were induration in 66 (23%) patients, erythema in 149 (52%), and negative in 73 (25%). The 5-year recurrence-free survival rates in patients with induration, erythema, and negative to PPD skin test were 89.4%, 65.5%, and 56.4%, respectively, with significant differences between the 3 groups. Univariate analysis demonstrated that tumor multiplicity (p¼0.025) and induration to PPD skin test (p<0.001) were significantly associated with tumor recurrence. On multivariate analysis only induration to PPD skin test was independently associated with tumor recurrence (Hazard ratio: HR of 0.321, p¼0.002). Seventy two (25%) patients experienced major side effects, including macrohematuria in 16 patients, high grade fever in 28, severe lower urinary tract symptoms in 19, and others in 19. Major side effects were observed in 22 (33%) patients with induration, in 40 (27%) with erythema, and in 10 (14%) with negative to PPD skin test, with significant difference between the 3 groups. On multivariate analysis only erythema to PPD skin test was independently associated with occurrence of major side effect (HR of 2.309, p¼0.03) CONCLUSIONS: The PPD skin test reaction before BCG therapy was highly associated with clinical outcome of tumor recurrence and occurrence of major side effects in patients with NMIBC treated with BCG therapy. . 197, No. 4S, Supplement, Sunday, May 14, 2017 cases. However, there are still no reliable indicators for identifying BCG relapsing tumor recurrence in NMIBC patients treated with BCG therapy. We examined here whether elevated pre-NLR and/or smoking status could be associated with BCG relapsing tumor recurrence. METHODS: We identified 1759 cases treated by TURBT for initially diagnosed NMIBC between 1999 and 2015 at our 4 institutions. Detailed information concerning smoking status and a full set of blood data were available for 947 of these 1759 cases. After excluding patients who were BCG refractory and BCG intolerant, 438 cases treated with BCG therapy were included in the present study. We evaluated the predictive factors for identifying BCG relapsing tumor recurrence, defined as recurrence after achieving a disease-free status by initial BCG instillations for 6 months. We assigned patients to the elevated pre-NLR group using a cut-off of NLR of more than 2.095 according to a calculation by receiver-operating curve analysis.
Source of
RESULTS: A total of 208 patients (47.5%) had elevated pre-NLR and 264 patients (60.3%) had a previous history of smoking. Patients with elevated pre-NLR were significantly older and had higher tumor stage as compared to their counterparts. A higher population of male patients was observed in the smoker group. The 5-year recurrence free survival (RFS) rate in patients with elevated pre-NLR was 63.2 AE 3.7%, which was significantly lower than that in those without elevated pre-NLR (77.9 AE 3.0%, p<0.001). The 5-year RFS rate in patients with a previous history of smoking was 66.0 AE 3.3%, which was significantly lower than that in that in the non-smoker group (78.2 AE 3.4%, p¼0.003). Multivariate analysis demonstrated that an elevated pre-NLR (hazard ratio: HR, 1.98, p<0.001) and a previous history of smoking (HR, 1.81, p¼0 .003) were independently associated with BCG relapsing tumor recurrence. CONCLUSIONS: Pre-NLR level and smoking status before BCG therapy might be useful information for predicting BCG relapsing tumor recurrence. Patients with a high pre-NLR level and positive smoking history are highly recommended to undergo early cystectomy due to their higher rate of BCG relapsing tumor recurrence. METHODS: We analyzed index pretreatment NMIBC tumors and matched germline DNA of 105 patients with a 341 cancer-associated gene panel in a CLIA-certified clinical laboratory. Representative hematoxylin and eosin slides were reviewed by a genitourinary pathologist to confirm grade, stage, and urothelial histology. Restaging TUR was performed in all HGT1 tumors.
RESULTS: To characterize the genomic landscape of NMIBC, we analyzed 105 tumors across the disease spectrum including LGTa (n¼23), HGTis (n¼12), HGTa (n¼32) and HGT1 (n¼38). The most frequently mutated genes in NMIBC tumors were TERT promoter (74%), FGFR3 (50%), KDM6A (47%), ARID1A (28%), PIK3CA (27%), KMT2D (24%), STAG2 (21%), and CDKN2A (17%). Of 105 tumors, 81% harbored at least one inactivating alteration in a chromatin-modifying gene. Alterations in the RTK/RAS/PIK3 pathway were present in 83% of tumors, including 58% of high-grade NMIBC tumors with either ERBB2 or FGFR3 alterations in a mutually exclusive pattern. Of 105 patients, 62 were treated uniformly with a 6-week induction course of BCG without maintenance. Genes altered with !5% frequency on the 341-gene panel were investigated for an association with recurrence after Bacillus Calmette-Guerin (BCG) therapy. On cox-regression analysis, only truncating mutations in the chromatin-modifying gene ARID1A were associated with recurrence after BCG (HR¼3.14 [95%CI¼1.51-6.51] p¼0.002) (Table 1) . This remained significant when adjusting for multiple comparisons (p¼0.04) and when including ARID1A missense mutations of unknown significance (HR¼3.08 [95%CI¼1.49-6.35] p¼0.002).
CONCLUSIONS: Next Generation Sequencing of index pretreatment NMIBC tumors showed an association between ARID1A mutations and recurrence after BCG therapy. Whether ARID1A mutations in NMIBC can serve as potential predictive or prognostic biomarkers or as therapeutic targets warrants further investigation. Moreover, the majority of NMIBC tumors had at least one potentially 00 actionable 00 alteration that could serve as a target in rationally designed trials of intravesical or systemic therapy. 
PD48-12
METHOD OF DETECTING BLADDER CANCER BY OPTICAL ANALYSIS OF BODILY FLUIDS
Danny Rabah*, Riyadh, Saudi Arabia INTRODUCTION AND OBJECTIVES: Cystoscopy remains the main stay of surveillance employed for the follow up of Bladder cancer patients. The present study aims to provide a new detection method which is completely non-invasive, does not require additional surgery, and which is more accurate than visual inspection techniques, using a new photodynamic diagnostic procedure to quantify certain cancer specific biomarker called Porphyrin, which selectively binds on to the bladder cancer tissues.
METHODS: Twenty bladder cancer patients and twenty healthy controls (all confirmed by cystoscopy) were invited to participate in the current clinical trial (NCT02101931), where 5 mg of 5-Aminolevulinic Acid (ALA) per kilogram body weight were administered for each
